Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F24%3A10483171" target="_blank" >RIV/00216208:11110/24:10483171 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/24:10483171
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=OAO7kb0vOM" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=OAO7kb0vOM</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.pnpbp.2024.111069" target="_blank" >10.1016/j.pnpbp.2024.111069</a>
Alternative languages
Result language
angličtina
Original language name
Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Original language description
The strategy for the development of new drugs for Alzheimer's disease (AD) recognizes that an effective therapy requires early therapeutic intervention and a multifactorial approach that considers the individual initiators of AD development. Current knowledge of AD includes the understanding of pathophysiology, risk factors, biomarkers, and the evolving patterns of biomarker abnormalities. This knowledge is essential in identifying potential molecular targets for new drug development. This review summarizes promising AD drug candidates, many of which are currently in phase 2 or 3 clinical trials. New agents are classified according to the Common Alzheimer's Disease Research Ontology (CADRO). The main targets of new drugs for AD are processes related to amyloid beta and tau neurotoxicity, neurotransmission, inflammation, metabolism and bioenergetics, synaptic plasticity, and oxidative stress. These interventions are aimed at preventing disease onset and slowing or eliminating disease progression. The efficacy of pharmacotherapy may be enhanced by combining these drugs with other treatments, antioxidants, and dietary supplements. Ongoing research into AD pathophysiology, risk factors, biomarkers, and the dynamics of biomarker abnormalities may contribute to the understanding of AD and offer hope for effective therapeutic strategies in the near future.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
<a href="/en/project/NU23-04-00032" target="_blank" >NU23-04-00032: Mitochondrial toxicity of tau protein oligomers and its regulation by drugs for Alzheimer's disease</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Progress in Neuro-Psychopharmacology & Biological Psychiatry
ISSN
0278-5846
e-ISSN
1878-4216
Volume of the periodical
134
Issue of the periodical within the volume
August
Country of publishing house
US - UNITED STATES
Number of pages
22
Pages from-to
111069
UT code for WoS article
001262103400001
EID of the result in the Scopus database
2-s2.0-85196794735